A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

M. J. Moore, C. Erlichman, L. Kaizer, S. Fine

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

Original languageEnglish (US)
Pages (from-to)555-557
Number of pages3
JournalAnti-cancer drugs
Volume4
Issue number5
StatePublished - Jan 1 1993

    Fingerprint

Keywords

  • 5-Fluorouracil
  • Interferon
  • Leucovorin
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Moore, M. J., Erlichman, C., Kaizer, L., & Fine, S. (1993). A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer. Anti-cancer drugs, 4(5), 555-557.